Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells

LONDON, October 24, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: CytRx Corporation (NASDAQ: CYTR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index advancing 3.42% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

CytRx Corp.'s stock rallied 8.99%, to close the day at $2.91. The stock recorded a trading volume of 1.57 million shares, above its three months average volume of 0.82 million shares. The company's shares oscillated between $2.68 and $2.97 during the session. Over the last three trading sessions and over the past one month, CytRx Corp.'s shares have gained 6.59% and 7.38%, respectively. However, the stock has declined 53.59% since the start of this year. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $4.12 is above its 50-day moving average of $2.93. Additionally, CytRx Corp.'s shares have a Relative Strength Index (RSI) of 48.14. Sign up and read the free notes on CYTR at:

http://www.Investor-Edge.com/CYTR-24Oct2014

On Thursday, shares in Vertex Pharmaceuticals Inc. recorded a trading volume of 1.26 million shares, higher than its three months average volume of 1.66 million shares. The stock ended the day at $108.09, which was 1.81% above its previous day's closing of $106.17, and registered an intraday range of $106.33 and $109.55. Vertex Pharmaceuticals Inc.'s stock has gained 3.17% in the previous three trading sessions, 10.14% in the last three months, and 45.48% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $99.28 and $83.63, respectively. Furthermore, shares of Vertex Pharmaceuticals Inc. have an RSI of 54.77. The complimentary notes on VRTX can be downloaded as in PDF format at:

http://www.Investor-Edge.com/VRTX-24Oct2014

Alexion Pharmaceuticals Inc.'s stock also rallied 7.30% to end Thursday's session at $185.92, hitting a new 52-week high of $186.47. The stock recorded a trading volume of 2.39 million shares, above its three months average volume of 1.19 million shares. The company's shares fluctuated between $177.72 and $186.47 during the session. Shares of the company traded at a PE ratio of 73.21. Alexion Pharmaceuticals Inc.'s shares have surged 39.91% since the beginning of 2014. Further, the stock has gained 10.54% over the previous three trading sessions and 17.17% in the last one month. The stock is trading above its 50-day and 200-day moving averages. Alexion Pharmaceuticals Inc.'s shares 50-day moving average of $166.94 is above its 200-day moving average of $161.63. Additionally, the stock has an RSI of 57.08. On the same day, Alexion Pharmaceuticals Inc. announced its Q3 FY 2014 financial results (period ended September 30, 2014). For Q3 FY 2014, the company reported GAAP net income attributable to Alexion Pharmaceuticals Inc. of $177.73 million, or $0.88 per diluted share. Register for free on Investor-Edge and access the latest research on ALXN at:

http://www.Investor-Edge.com/ALXN-24Oct2014

On Thursday, shares in Peregrine Pharmaceuticals Inc. fluctuated between $1.42 and $1.48 before ending the session 1.38% higher at $1.47. The stock reported a trading volume of 0.83 million shares, lower than its three months average volume of 1.08 million shares. Peregrine Pharmaceuticals Inc.'s shares have fallen by 2.00% in the previous three trading sessions and 6.37% in the past three months, while the stock has advanced 5.76% in the last one month. The stock is trading below its 50-day and 200-day moving averages of $1.50 and $1.73, respectively. Moreover, shares of Peregrine Pharmaceuticals Inc. have an RSI of 51.32. The complete research on PPHM is available for free at:

http://www.Investor-Edge.com/PPHM-24Oct2014

StemCells Inc.'s stock finished Thursday's session at the previous day's closing price of $1.16. A total of 0.26 million shares were traded, which was much below its three months average volume of 0.73 million shares. The stock vacillated between $1.15 and $1.18 during the session. Over the last one month and over the previous three months, StemCells Inc.'s shares have declined 10.08% and 32.95%, respectively. Additionally, from the beginning of 2014, the stock has fallen by 5.69%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $1.49 is greater than its 50-day moving average of $1.37. StemCells Inc.'s stock has an RSI of 39.40. Free in depth research on STEM is available at:

http://www.Investor-Edge.com/STEM-24Oct2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED